HIV entry: New insights and implications for patient management

Current Opinion in Infectious Diseases

Volumn 22, Issue 1, 2009, Pages 35-42

  Hughes, Amelia ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Attachment inhibitors; CCR5 antagonists; Fusion inhibitors; HIV entry inhibitors; HIV tropism

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; 8 [4 (2 BUTOXYETHOXY)PHENYL] 1,2,3,4 TETRAHYDRO 1 ISOBUTYL N [4 (1 PROPYL 1H IMIDAZOL 5 YLMETHYLSULFINYL)PHENYL] 1 BENZAZOCINE 5 CARBOXAMIDE; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EFAVIRENZ; ENFUVIRTIDE; HGS 004; IBALIZUMAB; INCB9471; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; PLACEBO; PLERIXAFOR; PRO 140; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCH 532706; SCH532706; SIFURVITIDE; UNCLASSIFIED DRUG; VICRIVIROC;

AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; PATIENT CARE; REVIEW; SIDE EFFECT; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS ENTRY; VIRUS LOAD;

CLINICAL TRIALS AS TOPIC; HIV; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; RECEPTORS, HIV; VIRUS INTERNALIZATION;

EID: 58849117640     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283213093     Document Type: Review

References (72)

1. Grover D, Copas A, Green H, et al. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother 2008; 61:705-713.
2. McDougal JS, Maddon PJ, Dalgleish AG, et al. The T4 glycoprotein is a cell surface receptor for the AIDS virus. Cold Spring Harb Symp Quant Biol 1986; 51:703-711.
3. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661 -666.
4. Feng Y, Broder C, Kennedy P, Berger E. HIV-1 entry cofactor: functional cDNA cloning of a seven transmembrane G protein coupled receptor. Science 1996; 272:872-877.
5. Panos G, Nelson M. HIV-1 tropism. Biomarkers Med 2007; 1:473-481.
6. Mueller MC, Bogner JR. Treatment with CCR5 antagonists: which patient may have a benefit. Eur J Med Res 2007; 12:441-452.
7. Alkhatib G, Berger EA. HIV coreceptors: from discovery and designation to new paradigms and promise. Eur J Med Res 2007; 12:375-384.
8. Panos, Nelson. Viral (HIV) entry: how does it work? In: Jager H, editor. Entry inhibitoren ! neue Formen der HIV therapy. Springer; 2008. pp. 1-10.
9. Sierra S, Kaiser R, Thielen A, Lenguer T. Genotypic coreceptor analysis. Eur J Med Res 2007; 12:453-462.
10. Berger E, Doms R, Fenyo E, et al. A new classification for HIV-1. Nature 1998; 391:240.
11. Sabeti P, Walsh E, Schaffner S, et al. The case for selection at CCR5-Delta 32. PLoS Biol 2005; 3:e378.
12. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-890.
13. Demarest J, Bonny T, Vavro C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects [abstract H1136]. In: Program and Abstracts of the 44th International Conference on Antimicrobial Agents and Chemotherapy; 30 October-2 November 2004; Washington, DC. Washington, DC: American Society for Microbiology; 2004.
14. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474.
15. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-872.
16. de Roda Husman AM, Schuitemaker H. Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol 1998; 6:244-249.
17. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
18. Hunt P, Martin J, Bates M, et al. CXCR4-tropic viruses are common among antiretroviral treated patients with detectable viremia and associated with lower treatment-mediated CD4 gains [abstract #43]. In: 13th Conference on Retroviruses and Opportunistic Infections; 6 June 2006; Denver, CO.
19. Moore JP, Kitchen SG, Pugach P, et al. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111-126.
20. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004; 17:7-16.
21. Whitcomb JM, Huang W, Fransen S, et al. Analysis of baseline enfuvirtide (t20) susceptibility and co-receptor tropism in two-phase III study populations [abstract #557]. In: 10th Conference on Retroviruses and Opportunistic Infections; 10-14 February 2003; Boston, MA.
22. Paxinos E, Fransen S, Huang W, et al. Measuring HIV-1 coreceptor tropism using a recombinant virus assay [abstract #2040]. In: Program and Abstracts of the 42th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27-30 September 2002; San Diego, CA.
23. Wilkin T, Su Z, Kuritzkes D, et al. Co-receptor tropism in patients screening for ACTG 5211, a phase 2 study of Vicriviroc, a CCR5 inhibitor [abstract #655], In: 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, CO.
24. Hoffman C. The epidemiology of HIV coreceptor tropism. Eur J Med Res 2007; 12:385-390.
25. Cilliers T, Nhlapo J, Coetzer M, et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003; 77:4449-4456.
26. Johnston ER, Zijenah LS, Mutetwa S, et al. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003; 77:7682-7688.
27. Patel MB, Hoffman NG, Swanstrom R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol 2008; 82:903-916.
28. Menu E, Reynes JM, Müller-Trutwin MC, et al. Predominance of CCR5- dependent HIV-1 subtype E isolates in Cambodia. J Acquir Immune Defic Syndr Hum Retroviral 1999; 20:481 -487.
29. Subbarao S, Vanichseni S, Hu DJ, et al. Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand. AIDS Res Hum Retroviruses 2000; 16:699-707.
30. Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007; 81:7885- 7893.
31. Tscherning C, Alaeus A, Fredriksson R, et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998; 241:181-188.
32. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45:28-33.
33. Bégaud E, Feindirongai G, Versmisse P, et al. Broad spectrum of coreceptor usage and rapid disease progression in HIV-1-infected individuals from Central African Republic. AIDS Res Hum Retroviruses 2003; 19:551 - 560.
34. Cilliers T, Willey S, Sullivan WM, et al. Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology 2005; 339:136-144.
35. Stawiski E, Whitcomb J, Coakley E, et al. Co-receptor tropism predictions based on V3 loop sequence in antiretroviral-experienced patients are specific but insensitive for the detection of CXCR4-using variants [abstract #1-1-1028], In: Program and Abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2007; Chicago, IL
36. Jensen MA, Li FS, van 't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 Env V3 loop sequences. J Virol 2003; 77:13376-13388.
37. Low AJ, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21:F17-F24.
38. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-575.
39. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study [abstract #WESS104]. In: 4th IAS conference; 22-25 July 2007; Sydney, Australia.
40. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies [abstract #792]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2006; Boston, MA.
41. Gulick R, Su Z, Flexner C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results [abstract #TUAB102]. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia.
42. Reeves J, Han D, Wilkin T, et al. An enhanced version of the trofile HIV coreceptor tropism assay predicts emergence of CXCR4 use in ACTG5211 vicriviroc trial samples [abstract #869]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
43. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732.
44. Carter NJ, Keating GM. Maraviroc. Drugs 2007; 67:2277-2288; discussion 2289-2290.
45. Nelson M, Fisher M, Gonzalez-Garcia J, et al. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc (MVC) plus an optimized background therapy (OBT) versus placebo (PBO) plus OBT in the MOTIVATE 1 and 2 trials [abstract #TUPE0119]. In: Program and Abstracts of the XVII International AIDS Conference; 3-8 August 2008; Mexico City, Mexico.
46. Hoepelman IM, Ayoub A, Heera J. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the Maraviroc Clinical Development Programme [poster LBP7.9/1]. In: 11th European AIDS Conference/ EACS; 24-27 October 2007; Madrid, Spain.
47. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a preexisting minority of CXCR4-using virus [abstract #56]. In: Program and Abstracts of the XVI HIV Drug Resistance Workshop; 12-16 June 2007; Barbados.
48. van der Ryst E, Westby M. Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials [abstract #H- 715]. In: Program and Abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2007; Chicago, IL.
49. Lewis M, Mori J, Simpson P. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials [abstract #871]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
50. Heera J, Saag M, Ive P, et al. Virological correlates associated with treatment failure at week 48 in the phase III study of maraviroc in treatment naïve patients [abstract #40LB]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
51. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment experienced adults: VICTOR-E1 48 week results [abstract #39LB]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
52. Dumond J, Patterson K, Pecha A, et al. Maraviroc (MVC) pharmacokinetics (PK) in blood plasma (BP) genital tract (GT) fluid and tissue in health female volunteers [abstract #135LBJ. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
53. Méchai F, Quertainmont Y, Sahali S, et al. Postexposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multiresistant HIV-infected source person. J Med Virol 2008; 80:9-10.
54. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials in treatment- experienced subjects [abstract #8000], In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
55. van De Ryst E, Meyer H, James M, et al. Maravaroc, changes in CD4 and tropism in ART-Experienced 1029 Study [Poster P393]. In: 8th International Conference on Drug Therapy in HIV Infection; 12-16 November 2006; Glasgow, Scotland.
56. Phillips A. Morbidity and mortality in the HAART era [abstract #8], In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
57. El-Sadr WM, Lundgren JD, Neaton JD, et al., Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283- 2296.
58. Zolopa A, Andersen J, Komarow L, et al. Immediate vs. deferred ART in the setting of acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG A5164 [abstract #142], In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
59. Pett A, Emery S, MacRae K, et al. Safety and activity of SCH532706, a small molecule chemokine receptor 5 antagonist in HIV-1 infected individuals [abstract #38]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
60. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of theanti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189:286-291.
61. Norris D, Morales J, Godofsky E, et al. TNX-355 in combination with OBR, achieves statistically significant viral load reduction and CD4 cell increase when compared with OBR alone in phase II study at 48 weeks [abstract #THLB0218], In: XVI International AIDS Conference; 13-18 August 2006; Toronto, ON.
62. Weinheimer S, D'arigo K, Fung M, et al. TNX-355 is active against enfuviritide resistanct HIV-1 [abstract #THLB0024]. In: XVI International AIDS Conference; 13-18 August 2006; Toronto, ON.
63. Olson W, Ketas T, Nagashima K, et al. Potency, breadth and durability of the antiviral activity of PRO 140, a novel inhibitor of CCR5-mediated HIV-1 entry [abstract #667]. In: 7th Conference on Retroviruses and Opportunistic Infections; 30 January-2 February 2000; San Francisco, CA.
64. Saag MS, Jacobson JM, Thompson M, et al. Antiviral effects and tolerability of the CCR5 monocloncal antibody PRO140: a proof of concept study in HIV infected individuals [abstract #WESS201]. In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia.
65. Cohen C, DeJesus E, Mills A, et al. Petent antiretroviral activity of once-daily CCR5 antagonist INCB009471 over 14 days monotherapy [abstract #TUAB106]. In: XV International AIDS Conference; 2007; Sydney, Australia.
66. Lalezari J, Yadavalli GK, Para M, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human lgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008; 197:721-727.
67. Baba M, Kanzaki N, Miyake H, et al. TAK-652, a novel small molecule CCR5 antagonist with potent antiHIV-1 activity [abstract #541]. In: 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston, MA.
68. Tremblay C, Giguel F, Chou T, et al. TAK-652, a novel small molecule CCR5 antagonist has favourable anti-HIV interactions with other antiretrovirals in vitro [abstract #542]. In: 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston, MA.
69. Saag M, Rosenkranz S, Becker S, et al. Proof of concept of antiretroviral aotivity of AMD11070 (an orally administered CXCR4 entry inhibitor): results of the first dosing cohort A studied in ACTG Protocol A5210 [abstract #512]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, CA.
70. Moyle G, DeJesus E, Boffito M, et al. CXCR4 antagonism: proof of activity with AMD11070 [abstract #511]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, CA.
71. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. Acquir Immune Defic Syndr 2004; 37:1253-1262.
72. He Y, Xiao Y, Song H, et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008; 283:11126-11134.